MOG

MOG

MOG 詳細

Molecule Name
Myelin-oligodendrocyte glycoprotein
分子の別称
MOG,BTN6,BTNL11,MOGIG2,NRCLP7,Myelin oligodendrocyte glycoprotein
Drug Development Progress
治験薬の数1
市販薬剤の数0
研究&開発段階Phase 2 Clinical
ターゲットの別称
NRCLP7,Myelin-oligodendrocyte glycoprotein,MOG,Myelin Oligodendrocyte Glycoprotein,MOG Ig-AluB,MOG Alpha-5,MOG AluA,MOG AluB,BTNL11,MOGIG2,BTN6
バックグランド
Myelin oligodendrocyte glycoprotein (MOG), is a single-pass transmembrane glycoprotein of the immunoglobulin (Ig) superfamily. MOG is a myelin protein exclusively expressed in the CNS at the outermost surface of myelin sheaths and oligodendrocyte membranes. This makes MOG a potential target of cellular and humoral immune responses in inflammatory demyelinating diseases. Due to its late postnatal developmental expression, MOG is an important marker for oligodendrocyte maturation.

MOG 製品リスト

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
MOG autologous T-lymphocyte cell therapy (ImCyse)Phase 2 ClinicalImcyse Sa
Multiple Sclerosis
詳細